Genetic and environmental determinants of lipid profile in Black and White youth: A study of four candidate genes

Ethnicity and Disease

Volumn 15, Issue 4, 2005, Pages 568-577

  Davis, Catherine L ^a   Wang, Xiaoling ^a   Sneider, Harold ^a,b   Treiber, Frank A ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Body mass index; Cardiovascular; Cholesterol; Continental population groups; HDL lipoproteins; Polymorphism; Risk factors; Triglycerides; Young adults

Indexed keywords

ALANINE; APOLIPOPROTEIN B; CHOLESTEROL; GLUTAMIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ALLELE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CAUCASIAN; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HOMOZYGOTE; HUMAN; JUVENILE; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; OBESITY; OUTCOMES RESEARCH; RACE DIFFERENCE; SCHOOL CHILD;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ALLELES; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, HDL; ENVIRONMENT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPIDS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, LDL; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 27844535294     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Ethel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or = 12 months) follow-up intravascular ultrasound. Circulation. 2003;108:2757-2762.
3. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation. 2001;104: 2815-2819.
4. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290:2271-2276.
5. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care. 1996;19:414-418.
6. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
7. Hokanson JE, Langefeld CD, Mitchell BD, et al. Pleiotropy and heterogeneity in the expression of atherogenic lipoproteins: the IRAS family study. Hum Hered. 2003;55:46-50.
8. Snyder EE, Walts B, Perusse L, et al. The human obesity gene map: the 2003 update. Obes Res. 2004;12:369-439.
9. Gillum RF. Distribution of waist-to-hip ratio, other indices of body fat distribution and obesity and associations with HDL cholesterol in children and young adults aged 4-19 years: The Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 1999;23:556-563.
10. Christensen B, Glueck C, Kwiterovich P, et al. Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the Prevalence Study of the Lipid Research Clinics Program. Pediatr Res. 1980;14:194-202.
11. Srinivasan SR, Wattigney W, Webber LS, Berenson GS. Race and gender differences in serum lipoproteins of children, adolescents, and young adults - emergence of an adverse lipoprotein pattern in white males: The Bogalusa Heart Study. Prev Med 1991;20: 671-684.
12. Whitty CJ, Brunner EJ, Shipley MJ, Hemingway H, Marmot MG. Differences in biological risk factors for cardiovascular disease between three ethnic groups in the Whitehall II study. Atherosclerosis. 1999;142:279-286.
13. American Heart Association. Heart disease and stroke statistics - 2005 update. In. Dallas, TX: American Heart Association; 2004.
14. Gartside P, Khoury P, Glueck C. Determinants of high-density lipoprotein cholesterol in blacks and whites: The second National Health and Nutrition Examination survey. Am Heart J. 1984; 108:641-651.
15. Wilson PWF. Lipids, lipases, and obesity: does race matter? Arterioscler Thromb Vasc Biol. 2000;20:1854-1856.
16. Vega GL, Clark LT, Tang A, Marcovina S, Grundy SM, Cohen JC. Hepatic lipase activity is lower in African American men than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Rsch. 1998;39:228-232.
17. Després JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: The Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000;20: 1932-1938.
18. Srinivasan SR, Ehnholm C, Wattigney WA, Bao W, Berenson GS. The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis. 1996;123:33-42.
19. Howard BV, Gidding S, Liu K. Association of Apolipoprotein E phenotype with plasma lipoproteins in African-Americans and white young adults. Am J Epidemiol. 1998;148: 859-868.
20. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis. 2001;159: 367-373.
21. Srinivasan SR, Li S, Chen W, Boerwinkle E, Berenson GS. R219K polymorphism of the ABCA1 gene and its modulation of the variations in serum high-density lipoprotein cholesterol and triglycerides related to age and adiposity in white versus black young adults. The Bogalusa heart study. Metabolism. 2003;52:930-934.
22. Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Hepatic lipase promoter C-514T polymorphism influences serial changes in HDL cholesterol levels since childhood: the Bogalusa Heart Study. Atherosclerosis. 2003;169:175-182.
23. Rajput-Williams J, Knott TJ, Wallis SC, et al. Variation of apolipoprotein-B gene is associated with obesity, high blood cholesterol levels, and increased risk of coronary heart disease. Lancet. 1988;2:1442-1446.
24. Saha N, Tay JS, Heng CK, Humphries SE. DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore. Clin Genet. 1993;44:113-120.
25. Fu Y, Katsuya T, Higaki J, et al. A common mutation of low-density lipoprotein receptor gene is associated with essential hypertension among Japanese. J Hum Hypertens. 2001;15: 125-130.
26. Boright Ap, Connelly PW, Brunt JH, Morgan K, Hegele RA. Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. J Hum Genet. 1998;43:153-159.
27. Salazar LA, Hirata MH, Giannini SD, et al. Effects of Ava II and Hinc II polymorphisms at the LDL receptor gene on serum lipid levels of Brazilian individuals with high risk for coronary heart disease. J Clin Lab Anal. 1999;13:251-258.
28. Salazar LA, Hirata MH, Forti N, et al. PVU II intron 15 polymorphism at the LDL receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil. Clin Chim Acta. 2000;293:75-88.
29. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.
30. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med. 2000;38:3-11.
31. Ventre J, Doebber T, Wu M, et al. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes. 1997;46: 1526-1531.
32. Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID. Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res. 2002;10;401-407.
33. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
34. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Endocrinol Metab. 2000;106:467-472.
35. Knoblauch H, Busjahn A, Muller-Myhsok B, et al. Peroxisome proliferator-activated receptor γ gene locus is related to body mass index and lipid values in healthy nonobese subjects. Arterioscler Thromb Vasc Biol. 1999;19: 2940-2944.
36. Gonzalez Sanchez JL, Serrano Rios MS, Fernandez Perez CF, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002;147:495-501.
37. Dysart JM, Treiber FA, Pflieger K, Davis H, Strong W. Ethnic differences in the myocardial and vascular reactivity to stress in normotensive girls. Am J Hypertens. 1994;7:15-22.
38. Treiber FA, McCaffrey F, Musante L, et al. Ethnicity, family history of hypertension and patterns of hemodynamic reactivity in boys. Psychosom Med. 1993;55:70-77.
39. Trégouët DA, Ducimetiere P, Tiret L. Testing association between candidate-gene markers and phenotype in related individuals, by use of estimating equations. Am J Hum Genet. 1997;61:189-199.
40. Hansen PS, Gerdes LU, Klausen IC, Gregersen N, Faergeman O. Polymorphisms in the apolipoprotein B-100 gene contributes to normal variation in plasma lipids in 464 Danish men born in 1948. Hum Genet. 1993;91:45-50.
41. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-287.
42. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha gene detectable by Ncol restriction of PCR product. Hum Mol Genet. 1992;1:353.
43. Zee RY, Schrader AP, Robinson BG, Griffiths LR, Morris BJ. Association of HincII RFLP of low density lipoprotein receptor gene with obesity in essential hypertensives. Clin Genet. 1995;47:118-121.
44. Long J. Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage Publications; 1997.
45. Selinger-Leneman H, Genin E, Norris JM, Khlat M. Does accounting for gene-environment (GxE) interaction increase the power to detect the effect of a gene in a multifactorial disease? Genet Epidemiol. 2003;24:200-207.
46. Stuhldreher WL, Orchard TJ, Donahue RP, Kuller LH, Gloninger MF, Drash AL. Cholesterol screening in childhood: sixteen-year Beaver County Lipid Study experience. J Pediatr. 1991;119:551-556.
47. Luepker RV, Rosamond WD, Murphy R, et al. Socioeconomic status and coronary heart disease risk factor trends. The Minnesota Heart Survey. Circulation. 1993;88:2172-2179.
48. Manhem K, Dotevall A, Wilhelmsen L, Rosengren A. Social gradients in cardiovascular risk factors and symptoms of Swedish men and women: the Goteborg MONICA Study 1995. J Cardiovasc Risk. 2000;7:359-368.
49. Amesen E, Forsdahl A. The Tromso heart study: coronary risk factors and their association with living conditions during childhood. J Epidemiol Community Health. 1985;39: 210-214.
50. Forsdahl A. Living conditions in childhood and subsequent development of risk factors for arteriosclerotic heart disease. The cardiovascular survey in Finnmark 1974-75. J Epidemiol Community Health. 1978;32:34-37.
51. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem. 1988;34: 2456-2459.
52. Craig S, Amin R, Russell D, Paradise N. Blood cholesterol screening: influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000;15:395-399.
53. Eberly LE, Stamler J, Neaten JD, Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003;163: 1077-1083.
54. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001;153:490-499.
55. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276: 882-888.
56. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22:1918-1923.
57. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents. Arch Pediatr Adolesc Med. 2003;157:821-827.
58. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001;286:2845-2848.
59. Li S, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. The peroxisome proliferator-activated receptor-gamma2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to aduhhood: the Bogalusa Heart Study. Diabetes. 2003;52:1265-1269.
60. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 2002;3:1-12.
61. Fernandez JR, Shiver MD. Using genetic admixture to study the biology of obesity traits and to map genes in admixed populations. Nutr Rev. 2004;62:S69-74.